Bisphosphonates and oesophageal cancer risk: Where are we now?

被引：3
作者：
Rozenberg, Serge [1 ]
Dutton, Susan [2 ]
机构：
[1] Univ Libre Bruxelles, CHU St Pierre, Dept Obstet & Gynaecol, B-1000 Brussels, Belgium
[2] Univ Oxford Wolfson Coll, Ctr Stat Med, Oxford OX2 6UD, England
来源：
MATURITAS | 2011年 / 68卷 / 02期
关键词：
Bisphosphonates; Oesophageal; Cancer; Risk; ORAL BISPHOSPHONATES;
D O I：
10.1016/j.maturitas.2010.10.010
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：106 / 108
页数：3
相关论文
共 50 条
  • [41] Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
    Chen, Ning
    Xu, Xiaoling
    Fan, Yun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [42] Fighting for Academic Surgical Oncology: Where Do We Come From, Where Are We Now, and Where Should We Head?
    Izbicki, Jakob R.
    ANNALS OF SURGERY, 2015, 262 (05) : 701 - 703
  • [43] Mobile Phones, Brain Tumors, and the Interphone Study: Where Are We Now?
    Swerdlow, Anthony J.
    Feychting, Maria
    Green, Adele C.
    Kheifets, Leeka
    Savitz, David A.
    ENVIRONMENTAL HEALTH PERSPECTIVES, 2011, 119 (11) : 1534 - 1538
  • [44] Disproportionality analysis of oesophageal toxicity associated with oral bisphosphonates using the FAERS database (2004-2023)
    Chen, Lin
    Dai, Zhicheng
    Song, Huangrong
    Zhang, Jiafeng
    Li, Tuo
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [45] Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here?
    Lippi, Giuseppe
    Plebani, Mario
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (12) : 2075 - 2080
  • [46] CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh, Arnab
    Mailankody, Sham
    Giralt, Sergio A.
    Landgren, C. Ola
    Smith, Eric L.
    Brentjens, Renier J.
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2056 - 2067
  • [47] Joint ESC/EASD Guidelines on Diabetes, where are we Now and where should we Go?
    Ryden, Lars
    Mellbin, Linda
    CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (06) : 690 - 692
  • [48] Advanced endoscopic therapeutics in Barrett's neoplasia: where are we now and where are we heading?
    Longcroft-Wheaton, Gaius
    Bhandari, Pradeep
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (05) : 543 - 545
  • [49] Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now?
    Berger, Manon
    Lechanteur, Anna
    Evrard, Brigitte
    Piel, Geraldine
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 605
  • [50] Molecular testing for thyroid nodules: Where are we now?
    Ferraz, Carolina
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2024, 25 (01) : 149 - 159
12345